Related Experiment Video
Updated: May 14, 2026

Co-immunoprecipitation Assay Using Endogenous Nuclear Proteins from Cells Cultured Under Hypoxic Conditions
Published on: August 2, 2018
Development of inhibitors of the PAS-B domain of the HIF-2α transcription factor
Jamie L Rogers1, Liela Bayeh, Thomas H Scheuermann
1Department of Biochemistry, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, Texas 75390-9038, United States.
Abstract:
Hypoxia inducible factors (HIFs) are heterodimeric transcription factors induced in a variety of pathophysiological settings, including cancer. We describe the first detailed structure-activity relationship study of small molecules designed to inhibit HIF-2α-ARNT heterodimerization by binding an internal cavity of the HIF-2α PAS-B domain. Through a series of biophysical characterizations of inhibitor-protein interactions (NMR and X-ray crystallography), we have established the structural requirements for artificial inhibitors of the HIF-2α-ARNT PAS-B interaction. These results may serve as a foundation for discovering therapeutic agents that function by a novel mode of action.
Insights
Researchers identified key structural features for small molecules that inhibit Hypoxia-inducible factors (HIFs) by blocking HIF-2α-ARNT interaction. This work lays the groundwork for novel cancer therapeutics targeting this pathway.
Area of Science:
- Molecular biology
- Structural biology
- Drug discovery
Background:
- Hypoxia-inducible factors (HIFs) are critical transcription factors involved in cellular responses to low oxygen.
- HIFs play a significant role in various pathophysiological conditions, notably in cancer development and progression.
- HIF-2α-ARNT heterodimerization is a key interaction in the HIF pathway, making it a target for therapeutic intervention.
Purpose of the Study:
- To conduct the first detailed structure-activity relationship (SAR) study of small molecules inhibiting HIF-2α-ARNT heterodimerization.
- To elucidate the structural requirements for small molecule inhibitors that bind to an internal cavity of the HIF-2α PAS-B domain.
- To provide a foundation for developing novel therapeutic agents targeting the HIF pathway.
Main Methods:
- Utilized a series of biophysical characterizations to study inhibitor-protein interactions.
- Employed Nuclear Magnetic Resonance (NMR) spectroscopy to assess binding and structural effects.
- Applied X-ray crystallography to determine high-resolution structures of inhibitor-protein complexes.
Main Results:
- Established the precise structural requirements for small molecules designed to inhibit HIF-2α-ARNT heterodimerization.
- Identified an internal cavity within the HIF-2α PAS-B domain as a binding site for these inhibitors.
- Characterized the molecular interactions governing the inhibition of HIF-2α-ARNT complex formation.
Conclusions:
- The study provides critical insights into the SAR of small molecule inhibitors targeting HIF-2α-ARNT interaction.
- The findings offer a structural basis for the rational design of novel therapeutic agents.
- This research may lead to new treatment strategies for diseases where HIF signaling is dysregulated, particularly cancer.
Related Concept Videos
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a DNA...
Inhibitors of Viral Protein Synthesis
Transcription Attenuation in Prokaryotes
There are several different mechanisms used to attenuate transcription. In ribosome mediated...
RNA Polymerase II Accessory Proteins
Inhibitors of Bacterial DNA Synthesis
The JAK-STAT Signaling Pathway

